About ABK Biomedical
ABK Biomedical is a company based in Halifax (Canada) founded in 2012. ABK Biomedical has raised $139.93 million across 7 funding rounds from investors including J P Morgan, Varian and Eight Roads Ventures. The company has 49 employees as of May 27, 2025. ABK Biomedical offers products and services including Eye90 microspheres and Easi-Vue embolic microspheres. ABK Biomedical operates in a competitive market with competitors including RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and Starget Pharma, among others.
- Headquarter Halifax, Canada
- Employees 49 as on 27 May, 2025
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Abk
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$139.93 M (USD)
in 7 rounds
-
Latest Funding Round
$35 M (USD), Series D
Oct 14, 2025
-
Investors
J P Morgan
& 6 more
-
Employee Count
49
as on May 27, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ABK Biomedical
ABK Biomedical offers a comprehensive portfolio of products and services, including Eye90 microspheres and Easi-Vue embolic microspheres.
Y90 radioembolization device for liver cancer treatment
Product for embolization of tumors and malformations
People of ABK Biomedical
Unlock access to complete
Funding Insights of ABK Biomedical
ABK Biomedical has successfully raised a total of $139.93M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $35 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ABK Biomedical
ABK Biomedical has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include J P Morgan, Varian and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Santé is engaged in healthcare and technology investment management.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked | |
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked |
Investor details for ABK Biomedical
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ABK Biomedical
Investment portfolio details for ABK Biomedical
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ABK Biomedical
Detailed financials for ABK Biomedical
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Abk Biomedical Comparisons
Peer comparison for ABK Biomedical
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ABK Biomedical
ABK Biomedical operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RefleXion, Alpha Tau Medical, Mevion Medical Systems, ZAP-X and Starget Pharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biology-guided radiotherapy systems are provided for cancer treatment.
|
|
| Locked | Locked | Locked |
Radiotherapy technique for solid tumors is developed using alpha-emitting seeds.
|
|
| Locked | Locked | Locked |
Proton therapy systems are supplied for cancer radiation treatment.
|
|
| Locked | Locked | Locked |
Developer of gyroscopic radiosurgery platform
|
|
| Locked | Locked | Locked |
Targeted radiopharmaceuticals are developed for solid tumor treatment.
|
Detailed competitors of ABK Biomedical
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Abk Biomedical
Complete news archive for ABK Biomedical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ABK Biomedical
ABK Biomedical was founded in 2012.
ABK Biomedical is headquartered in Halifax, Canada. It is registered at Halifax, Nova Scotia, Canada.
ABK Biomedical is a funded company, having raised a total of $139.93M across 7 funding rounds to date.
As of May 27, 2025, the latest employee count at ABK Biomedical is 49.
ABK Biomedical was founded in 2012 in Halifax, Canada, within the biomedical sector. Embolic medical devices are developed for treating benign and malignant hypervascular tumors. Eye90 microspheres, designed for Y-90 radioembolization, are used in liver tumor therapy and enable CT imaging for dosimetry. Easi-Vue embolic microspheres are provided for bland embolization, allowing visualization at target sites. Operations focus on device innovation for oncology applications.
ABK Biomedical's top competitors include RefleXion, Alpha Tau Medical and Starget Pharma.
ABK Biomedical offers Eye90 microspheres and Easi-Vue embolic microspheres.
ABK Biomedical has 7 investors. Key investors include J P Morgan, Varian, Eight Roads Ventures, Santé, and F-Prime Capital.